We are live on
!
Find out more
GTC
Ghost Tree Capital Portfolio holdings
AUM
$331M
1-Year Est. Return
70.11%
This Fund
S&P 500
This Quarter
Est. Return
+9.51%
1 Year Est. Return
+70.11%
3 Year Est. Return
+265.05%
5 Year Est. Return
+3,034.98%
10 Year Est. Return
+22,104.75%
AUM
$470M
AUM Growth
+$131M
(+38%)
Cap. Flow
+$115M
Cap. Flow
% of AUM
24.5%
Top 10 Holdings %
Top 10 Hldgs %
48.76%
Holding
67
New
21
Increased
15
Reduced
13
Closed
12
Top Buys
| 1 |
TSRO
TESARO, Inc.
TSRO
|
+$15.9M |
| 2 |
Invesco CurrencyShares Swiss Franc Trust
FXF
|
+$12.3M |
| 3 |
ECYT
Endocyte, Inc. Common Stock
ECYT
|
+$10.3M |
| 4 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$10.2M |
| 5 |
Travere Therapeutics
TVTX
|
+$10M |
Top Sells
| 1 |
MRSN
Mersana Therapeutics
MRSN
|
+$10.7M |
| 2 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$10.2M |
| 3 |
Arrowhead Research
ARWR
|
+$9.52M |
| 4 |
IMMU
Immunomedics Inc
IMMU
|
+$8.67M |
| 5 |
Exelixis
EXEL
|
+$8.61M |
Sector Composition
| 1 | Healthcare | 68.42% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $47.9M | 10.19% |
500,000
+495,000
| +9,900% | +$48M |
|
2
Sarepta Therapeutics
SRPT
$1.82B
| $33.9M | 7.21% |
210,000
+35,000
| +20% | +$4.78M |
|
3
PTC Therapeutics
PTCT
$6.52B
| $23.5M | 5% |
500,000
-175,000
| -26% | -$7.24M |
|
|
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $20.5M | 4.36% |
435,300
-64,700
| -13% | -$3.6M |
|
|
ECYT
5
DELISTED
Endocyte, Inc. Common Stock
ECYT
| $19.5M | 4.15% |
1,100,000
+600,000
| +120% | +$10.3M |
|
|
IMMU
6
DELISTED
Immunomedics Inc
IMMU
| $18.4M | 3.91% |
883,823
-366,177
| -29% | -$8.67M |
|
|
TSRO
7
DELISTED
TESARO, Inc.
TSRO
| $17.6M | 3.73% |
+450,000
| New | +$15.9M |
|
|
DRNA
8
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $16.8M | 3.57% |
1,100,000
+440,000
| +67% | +$6.4M |
|
9
Ascendis Pharma A/S
ASND
$17.1B
| $15.9M | 3.39% |
225,000
+50,000
| +29% | +$3.44M |
|
10
Alnylam Pharmaceuticals
ALNY
$35.7B
| $15.3M | 3.26% |
175,000
-35,000
| -17% | -$3.52M |
|
|
MRTX
11
PUT
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $14.1M | 3% |
+300,000
| New | +$16.7M |
|
|
12
Invesco CurrencyShares Swiss Franc Trust
FXF
$420M
| $12.3M | 2.61% |
+128,700
| New | +$12.3M |
|
13
Assembly Biosciences
ASMB
$531M
| $12.1M | 2.57% |
27,083
+7,500
| +38% | +$3.51M |
|
|
BLUE
14
DELISTED
bluebird bio
BLUE
| $10.9M | 2.33% |
5,790
-2,316
| -29% | -$4.78M |
|
15
CALL
Acadia Pharmaceuticals
ACAD
$4.38B
| $10.4M | 2.21% |
+500,000
| New | +$7.87M |
|
|
16
Acadia Pharmaceuticals
ACAD
$4.38B
| $10.4M | 2.21% |
500,000
-35,000
| -7% | -$551K |
|
|
17
Travere Therapeutics
TVTX
$5.27B
| $10.1M | 2.14% |
+350,000
| New | +$10M |
|
|
ZGNX
18
DELISTED
Zogenix, Inc.
ZGNX
| $9.92M | 2.11% |
+200,000
| New | +$10.2M |
|
19
Rocket Pharmaceuticals
RCKT
$376M
| $9.85M | 2.09% |
400,000
+50,000
| +14% | +$1.08M |
|
|
OBSV
20
DELISTED
ObsEva SA Ordinary Shares
OBSV
| $9.65M | 2.05% |
535,000
+135,000
| +34% | +$1.98M |
|
21
argenx
ARGX
$53.8B
| $9.48M | 2.02% |
125,000
-25,000
| -17% | -$2.22M |
|
22
Larimar Therapeutics
LRMR
$384M
| $8.77M | 1.86% |
62,500
+53,978
| +633% | +$6.55M |
|
|
PTLA
23
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $7.99M | 1.7% |
+300,000
| New | +$9.79M |
|
|
TCDA
24
DELISTED
Tricida, Inc. Common Stock
TCDA
| $7.64M | 1.62% |
250,000
+63,981
| +34% | +$1.88M |
|
|
BHVN
25
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $7.51M | 1.6% |
+200,000
| New | +$7.36M |
|
Similar funds
SF
AFS
SFA
E
OHCM
MC
BRA
S
Ghost Tree Capital's Q3 2018 Portfolio in Review
As of Q3 2018, Ghost Tree Capital held 67 positions worth $470M, up 38% from $340M the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Ghost Tree Capital deployed $115M of net new capital in Q3 2018, opening 21 new positions and adding to 15 existing holdings. Its largest new stake was TESARO, Inc.: 450,000 shares worth $17.6M.
By sector, the portfolio is most concentrated in Healthcare at 68% of assets, down from 84% a quarter earlier.
On the sell side, the largest reduction was Global Blood Therapeutics, Inc., an estimated $10.2M trimmed.
- Ghost Tree Capital's largest Q3 2018 buy was TESARO, Inc.: 450,000 shares worth $17.6M.
- Ghost Tree Capital added most to Endocyte, Inc. Common Stock in Q3 2018, an estimated $10.3M increase.
- Ghost Tree Capital's biggest Q3 2018 reduction was Global Blood Therapeutics, Inc., cutting an estimated $10.2M.
- Ghost Tree Capital fully exited Mersana Therapeutics in Q3 2018, selling an estimated $10.7M.
- Ghost Tree Capital's ten largest holdings make up 49% of its $470M portfolio in Q3 2018.
- Ghost Tree Capital opened 21 new positions and closed 12 in Q3 2018.
- Ghost Tree Capital's portfolio value rose 38% quarter-over-quarter to $470M.
Based on Ghost Tree Capital's 13F filing for Q3 2018, filed 14 Nov 2018.